AC Immune Q3, update

 

• ACI-7104.056 VacSYn Phase 2 trial in Parkinson’s disease (PD) on track to report interim safety and immunogenicity data
• Prescreening rate for Phase 2b Retain trial of JNJ-2056 (ACI-35.030) in Alzheimer’s disease (AD) triggered CHF 24.6 million milestone under agreement
• JNJ-2056 received Fast Track designation from the U.S. FDA
• Cash of CHF 157.9 million at the end of September, plus the CHF 24.6 million milestone payment received in October, provides runway into 2027

https://www.globenewswire.com/news-release/2024/11/05/2974792/0/en/AC-Immune-Reports-Third-Quarter-2024-Financial-Results-and-Provides-a-Corporate-Update.html